Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

06 Mar 2024
Cell Therapy
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences: Leerink Partners Global Biopharma Conference Tuesday, March 12, 2024 at 10:40 a.m. ET in Miami, FL Jefferies Biotech on the Bay Summit Wednesday, March 13, 2024 in Miami, FL UBS Virtual CNS Day Monday, March 18, 2024 A live and achieved webcast of the Company’s presentation at the Leerink Partners Global Biopharma Conference can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. About Intra-Cellular Therapies Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit . Contact: Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333 Burns McClellan, Inc. Cameron Radinovic cradinovic@burnsmc.com 212-213-0006
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.